Guardant Health to Appeal Federal Court Ruling in TwinStrand Patent Dispute
Guardant Health, a precision oncology company focused on advancing cancer detection, treatment selection and monitoring through blood-based technologies, has announced plans to appeal a final judgment issued by the U.S. District Court for the District of Delaware in an intellectual property dispute involving TwinStrand Biosciences, Inc. and the University of Washington.
The legal dispute centers on patent claims asserted against Guardant Health by TwinStrand Biosciences and the University of Washington. Guardant has stated that it strongly disagrees with the court’s decision and intends to challenge the judgment through the appeals process. At the same time, execution of the final judgment and collection of any potential royalties have been stayed while the appeal proceeds.
The development represents another stage in a long-running intellectual property dispute involving technologies used in precision oncology and liquid biopsy testing. For Guardant, the company’s appeal reflects its continued position that its products and research and development activities do not infringe the patents at issue.
Guardant Plans to Challenge the Judgment
Guardant Health said it will promptly appeal the final judgment issued by the federal district court. The company emphasized its confidence in the underlying strength of its intellectual property portfolio and the research and development work supporting its cancer-testing technologies.
John Saia, Chief Legal Officer of Guardant Health, said the company strongly disagrees with the decision and intends to seek its reversal through the appellate process. He also expressed confidence that Guardant will ultimately prevail.
The appeal will move the dispute beyond the district court and into further judicial review. Guardant is pursuing appeals before the U.S. Court of Appeals for the Federal Circuit, the federal appellate court that has jurisdiction over patent-related cases.
Because the execution of the judgment and collection of potential royalties have been stayed pending the appeal, Guardant does not currently face immediate implementation of the royalty obligations described in the judgment. The stay provides the company with an opportunity to continue its legal challenge while the appellate proceedings move forward.
Dispute Involves TwinStrand Biosciences and University of Washington
The underlying litigation was brought against Guardant by TwinStrand Biosciences and the University of Washington and involves intellectual property claims related to technologies used in the company’s precision oncology activities.
Patent disputes can be particularly significant for companies operating in the diagnostics and biotechnology sectors because intellectual property rights can affect the development, commercialization and delivery of innovative testing technologies. Liquid biopsy companies such as Guardant rely on complex technological platforms to identify and analyze biological signals from blood samples, making patent protection and freedom to operate important components of their businesses.
Guardant has maintained that it did not infringe the patents asserted in the litigation. The company is continuing to challenge the validity of the patents through proceedings before the U.S. Patent and Trademark Office (USPTO).
According to Guardant, both TwinStrand patents involved in the dispute have been preliminarily invalidated in the company’s ongoing challenges before the USPTO. These proceedings are separate from the district court litigation and represent another avenue through which Guardant is contesting the intellectual property claims.
The company is therefore pursuing multiple legal avenues as it seeks to overturn the district court judgment and challenge the patents at issue.
Scope of Potential Royalties Limited by Court Order
One important aspect of the latest development concerns the products that could potentially be subject to royalties.
Guardant said the order published on Friday specifically defines the products included within the scope of potential royalties based on products that existed at the time of the trial in 2023. The company noted that many of those products have since been discontinued or significantly upgraded.
This distinction could be important for Guardant’s current product portfolio. According to the company, the current versions of Guardant Reveal and Guardant Shield are excluded from the order and therefore are not subject to the potential royalties described in the judgment.
Guardant Reveal and Guardant Shield are part of the company’s portfolio of blood-based cancer-testing technologies. The company has continued to develop and update its technology platforms since the 2023 trial, meaning that the products available today may differ materially from versions that were on the market or under development at the time of the original proceedings.
The company’s statement indicates that these technological changes could reduce the potential impact of the judgment on its current operations.
Guardant Highlights Product Development and Technology Updates
Guardant also pointed to improvements made to Guardant360 and related services since the time of the original trial.
The company said it has validated design improvements to Guardant360 and associated services that would exclude their impact from potential ongoing royalties under the decision.
This reflects the importance of continued research and development in precision oncology. As diagnostic technologies evolve, companies regularly make modifications to testing platforms, laboratory processes, analytical methods and other components of their products.
Guardant’s position is that changes made to its technologies and product designs are relevant to determining whether current products would fall within the scope of any potential royalty obligations.
The company’s latest statement therefore distinguishes between technologies that existed during the 2023 trial and the updated platforms it currently uses.
Company Maintains It Did Not Infringe the Patents
Despite the federal district court judgment, Guardant continues to maintain that it did not infringe the patents asserted by TwinStrand Biosciences and the University of Washington.
The company’s position is supported by its ongoing efforts to challenge the validity of the patents through the USPTO. Guardant said both patents have been preliminarily invalidated in those proceedings.
However, the legal process is not necessarily concluded by a preliminary determination. Patent validity disputes can involve multiple stages of review and appeal, and the ultimate outcome may depend on decisions from administrative bodies and courts.
Guardant is consequently continuing its legal efforts on multiple fronts. In addition to the proceedings before the USPTO, the company is pursuing appeals before the U.S. Court of Appeals for the Federal Circuit.
The outcome of those proceedings could have implications for the final resolution of the intellectual property dispute and any potential financial obligations associated with the patents.
Potential Financial Impact Remains Subject to Appeal
The stay on execution of the final judgment and collection of potential royalties means that the financial implications of the district court ruling remain subject to the outcome of the appeal.
For investors and stakeholders, this creates an important distinction between the court’s current judgment and Guardant’s ultimate financial exposure. The company has indicated that the potential royalty scope is limited to certain products that existed at the time of the 2023 trial, while newer or significantly upgraded products may be outside the scope of the order.
Guardant’s statement also suggests that product discontinuations and technological improvements could further limit the effect of any royalty obligations.
Nevertheless, the final financial outcome cannot be determined until the relevant legal proceedings are resolved. The appeal could result in changes to the judgment, while the separate patent challenges could affect the underlying intellectual property claims.
Importance of Intellectual Property in Precision Oncology
The dispute highlights the broader importance of intellectual property protection within the precision oncology industry.
Precision oncology companies invest heavily in research, technology development and clinical validation to create diagnostic tools that can identify cancer-related signals, help physicians understand disease characteristics and support treatment decisions.
Blood-based cancer testing, commonly referred to as liquid biopsy, has become an important area of innovation. These technologies seek to detect and analyze biomarkers found in blood, potentially providing information without relying exclusively on traditional tissue biopsies.
As companies develop increasingly sophisticated testing platforms, intellectual property disputes can emerge over laboratory techniques, sequencing technologies, analytical approaches and other components of the diagnostic process.
For companies such as Guardant, maintaining a strong intellectual property position is therefore closely connected to long-term innovation and commercialization strategies.
Guardant’s decision to appeal demonstrates the company’s intention to defend its interpretation of its technology and intellectual property rights. Its separate challenges before the USPTO also show that the company is contesting the patents themselves rather than focusing solely on the financial consequences of the district court judgment.
Guardant Continues Focus on Precision Oncology
While the legal dispute continues, Guardant remains focused on developing and commercializing technologies designed to improve cancer detection and management.
The company describes itself as a leading precision oncology company, with technologies intended to support different stages of the cancer care pathway. Its product portfolio has evolved significantly, and the company has continued investing in technology improvements and research and development.
The latest legal development does not change Guardant’s stated confidence in its products or intellectual property. Instead, the company is positioning the appeal as an important step in protecting its technology platform and challenging what it believes is an incorrect decision.
The company’s comments also emphasize that several products identified in connection with the original trial have since been discontinued or substantially upgraded. This could be relevant as the courts consider the scope and applicability of any potential royalty obligations.
Appeal Will Determine Next Stage of Dispute
The next stage of the dispute will depend on the appellate process. Guardant has indicated that it intends to pursue an appeal before the U.S. Court of Appeals for the Federal Circuit and continue its challenges involving the patents before the USPTO.
The stay of the district court judgment means that potential royalty collection will remain paused while the appeal proceeds. The eventual outcome could determine whether the judgment remains in place, is modified or is overturned.
For now, Guardant is maintaining that its products do not infringe the asserted patents and that the patents themselves face significant challenges through the patent-review process.
The company’s latest announcement therefore combines a legal challenge with an update on the potential scope of financial exposure. Guardant says current versions of Guardant Reveal and Guardant Shield are excluded from the royalty order, while validated design improvements to Guardant360 and related services are expected to exclude their impact from potential ongoing royalties.
As the appeal and patent challenges move forward, the case remains an important intellectual property matter for Guardant Health and the broader precision oncology sector. The final resolution could influence the company’s legal obligations while also providing further clarity around the intellectual property landscape surrounding advanced cancer diagnostic technologies.
Source link: https://investors.guardanthealth.com/
